Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.

doi:10.1001/jamaoncol.2020.6252

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.

JAMA oncology - 1 Feb 2021

Samadder N Jewel, Riegert-Johnson Douglas, Boardman Lisa, Rhodes Deborah, Wick Myra, Okuno Scott, Kunze Katie L, Golafshar Michael, Uson Pedro L S, Mountjoy Luke, Ertz-Archambault Natalie, Patel Neej, Rodriguez Eduardo A, Lizaola-Mayo Blanca, Lehrer Michael, Thorpe Cameron S, Yu Nathan Y, Esplin Edward D, Nussbaum Robert L, Sharp Richard R, Azevedo Cindy, Klint Margaret, Hager Megan, Macklin-Mantia Sarah, Bryce Alan H, Bekaii-Saab Tanios S, Sekulic Aleksandar, Stewart A Keith

Abstract excerpt

IMPORTANCE: Hereditary factors play a key role in the risk of developing several cancers. Identification of a germline predisposition can have important implications for treatment decisions, risk-reducing interventions, cancer screening, and germline testing. OBJECTIVE: To examine the prevalence of pathogenic germline variants (PGVs) in patients with cancer using a universal testing approach compared with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Genetic factors in colorectal cancer

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Genomics and Rare Diseases

Share to Germ-Line Mutation

Share to Neoplastic Syndromes, Hereditary

Source

Open in PubMed Open full text

Identifiers

PMID: 33126242
DOI: 10.1001/jamaoncol.2020.6252
PMCID: PMC7600058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.PMID 33126242Read ↗

Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.Semantic proximity Read ↗

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.Semantic proximity Read ↗

Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.Semantic proximity Read ↗

Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients.Semantic proximity Read ↗

Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study.Semantic proximity Read ↗

Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel.Semantic proximity Read ↗

Germline Genetic Testing After Cancer DiagnosisSemantic proximity Read ↗

Clinical Integration of Germline Findings from a Tumor Testing Precision Medicine ProgramSemantic proximity Read ↗

Consideration for Multigene Panel Testing Outside of Cancer-Specific Genetic Testing.Semantic proximity Read ↗

Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer.Semantic proximity Read ↗

Germline pathogenic variants identification through Comprehensive Cancer Genome ProfilingSemantic proximity Read ↗

Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.